ERIS LIFESCIENCES Financial Statement Analysis
|
||
|
The Revenues of ERIS LIFESCIENCES have decreased by -88.08% YoY .
The Earnings Per Share (EPS) of ERIS LIFESCIENCES has decreased by -10.41 % YoY. |
||
ERIS LIFESCIENCES Last 5 Annual Financial Results
[BOM: 540596|NSE : ERIS]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹2,009 Cr | ₹16,851 Cr | ₹1,347 Cr | ₹1,212 Cr | ₹1,074 Cr |
| Expenses | ₹1,334 Cr | ₹11,484 Cr | ₹862 Cr | ₹781 Cr | ₹706 Cr |
| Operating Profit (Excl OI) | ₹675 Cr | ₹5,367 Cr | ₹485 Cr | ₹431 Cr | ₹368 Cr |
| Other Income | ₹24 Cr | ₹112 Cr | ₹26 Cr | ₹8.71 Cr | ₹16 Cr |
| Interest | ₹85 Cr | ₹262 Cr | ₹4.22 Cr | ₹1.98 Cr | ₹2.30 Cr |
| Depreciation | ₹183 Cr | ₹1,171 Cr | ₹65 Cr | ₹43 Cr | ₹50 Cr |
| Profit Before Tax | ₹431 Cr | ₹4,046 Cr | ₹442 Cr | ₹394 Cr | ₹331 Cr |
| Profit After Tax | ₹397 Cr | ₹3,742 Cr | ₹406 Cr | ₹355 Cr | ₹297 Cr |
| Consolidated Net Profit | ₹392 Cr | ₹3,822 Cr | ₹406 Cr | ₹355 Cr | ₹296 Cr |
| Earnings Per Share (Rs) | ₹25.83 | ₹28.83 | ₹28.10 | ₹29.88 | ₹26.16 |
| PAT Margin (%) | 12.61 | 18.78 | 21.20 | 29.09 | 28.53 |
| ROE(%) | 13.81 | 16.64 | 18.25 | 23.33 | 24.78 |
| ROCE(%) | 13.59 | 12.37 | 17.30 | 25.29 | 27.60 |
| Total Debt/Equity(x) | 0.85 | 1.06 | 0.38 | 0.02 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 20,042.3 Cr |
| Revenue (TTM) | : | ₹ 3,129.4 Cr |
| Net Profit(TTM) | : | ₹ 647.4 Cr |
| EPS (TTM) | : | ₹ 46.7 |
| P/E (TTM) | : | 31.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ERIS LIFESCIENCES | 4.4% | -0.9% | -20.3% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.7% | -2.3% | 8% |
| DIVIS LABORATORIES | 2% | -2.2% | 1.5% |
| TORRENT PHARMACEUTICALS | -1.8% | -0.1% | 36.7% |
| CIPLA | -2% | -3.3% | -9.9% |
| DR REDDYS LABORATORIES | -0.6% | -3.8% | -6.9% |
| MANKIND PHARMA | 1.5% | -6.4% | 1% |
| LUPIN | 3.5% | 3% | 16.4% |
| ZYDUS LIFESCIENCES | -1.6% | 2.9% | 10.2% |
ERIS LIFESCIENCES Revenues
[BOM: 540596|NSE : ERIS]
| Y-o-Y | -88.08 % |
| 5 Yr CAGR | 16.95 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹2,009 Cr | -88.08 | |
| Mar2024 | ₹16,851 Cr | 1,151.00 | |
| Mar2023 | ₹1,347 Cr | 11.15 | |
| Mar2022 | ₹1,212 Cr | 12.83 | |
| Mar2021 | ₹1,074 Cr | - | |
ERIS LIFESCIENCES Operating Profit
[BOM: 540596|NSE : ERIS]
| Y-o-Y | -87.43 % |
| 5 Yr CAGR | 16.38 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹675 Cr | -87.43 | |
| Mar2024 | ₹5,367 Cr | 1,006.63 | |
| Mar2023 | ₹485 Cr | 12.60 | |
| Mar2022 | ₹431 Cr | 17.09 | |
| Mar2021 | ₹368 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 5.46 % |
| 5 Yr CAGR | -0.49 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 33.59% | 5.46 | |
| Mar2024 | 31.85% | -11.55 | |
| Mar2023 | 36.01% | 1.32 | |
| Mar2022 | 35.54% | 3.77 | |
| Mar2021 | 34.25% | - | |
ERIS LIFESCIENCES Profit After Tax
[BOM: 540596|NSE : ERIS]
| Y-o-Y | -89.74 % |
| 5 Yr CAGR | 7.23 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹392 Cr | -89.74 | |
| Mar2024 | ₹3,822 Cr | 841.01 | |
| Mar2023 | ₹406 Cr | 14.35 | |
| Mar2022 | ₹355 Cr | 19.78 | |
| Mar2021 | ₹296 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -32.85 % |
| 5 Yr CAGR | -18.46 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 12.61 % | -32.85 | |
| Mar2024 | 18.78 % | -11.42 | |
| Mar2023 | 21.2 % | -27.12 | |
| Mar2022 | 29.09 % | 1.96 | |
| Mar2021 | 28.53 % | - | |
ERIS LIFESCIENCES Earnings Per Share (EPS)
[BOM: 540596|NSE : ERIS]
| Y-o-Y | -10.41 % |
| 5 Yr CAGR | -0.32 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹26 | -10.41 | |
| Mar2024 | ₹29 | 2.60 | |
| Mar2023 | ₹28 | -5.96 | |
| Mar2022 | ₹30 | 14.22 | |
| Mar2021 | ₹26 | - | |
ERIS LIFESCIENCES Return on Capital Employed (ROCE)
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 9.86 % |
| 5 Yr CAGR | -16.23 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 13.59% | 9.86 | |
| Mar2024 | 12.37% | -28.50 | |
| Mar2023 | 17.3% | -31.59 | |
| Mar2022 | 25.29% | -8.37 | |
| Mar2021 | 27.6% | - | |
ERIS LIFESCIENCES Share Price vs Sensex
| Current Share Price | : | ₹1,446.1 |
| Current MarketCap | : | ₹ 20,042.3 Cr |
| Updated EOD on | : | Jun 19,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ERIS LIFESCIENCES | 4.4% |
-0.9% |
-20.3% |
| SENSEX | 1.7% |
2.1% |
-6% |
ERIS LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 250 SMALLCAP INDEX | 3.7% | 6% | 2.2% |
| BSE 400 MIDSMALLCAP INDEX | 3.4% | 4.1% | 4% |
| BSE 1000 | 2.5% | 3.2% | 0.4% |
| BSE 500 | 2.4% | 2.8% | 0.1% |
| BSE HEALTHCARE | 1% | 0.6% | 8.8% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 500 | 4% | 7.2% | NA |
| NIFTY SMALLCAP 250 | 3.7% | 6.3% | 2.5% |
| NIFTY SMALLCAP250 MOMENTUM QUALITY 100 INDEX | 3.5% | 3.5% | -1.8% |
| NIFTY MIDSMALLCAP400 50:50 | 3.5% | 4.5% | NA |
| NIFTY 500 EQUAL WEIGHT | 3.4% | 4.8% | 3.1% |
You may also like the below Video Courses
FAQ about ERIS LIFESCIENCES Financials
How the annual revenues of ERIS LIFESCIENCES have changed ?
The Revenues of ERIS LIFESCIENCES have decreased by -88.08% YoY .
How the Earnings per Share (EPS) of ERIS LIFESCIENCES have changed?
The Earnings Per Share (EPS) of ERIS LIFESCIENCES has decreased by -10.41 % YoY .
Check out Intrinsic Value of Peers of ERIS LIFESCIENCES
Compare Stock Analytics of Peers of ERIS LIFESCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
